Agilent Technologies, Inc. (A) Stock Analysis and Metrics

Agilent Technologies

NYSE: A

$133.98 ▼ -0.31 (-0.23%)

At close: Jul 13, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap37.61 Bn

P/E26.60

P/S5.20

Div. Yield0.01

ROIC (Qtr)0.00

Total Debt (Qtr)304.00 Mn

Revenue Growth (1y) (Qtr)10.01

Add ratio to table…

About

Agilent Technologies, Inc. is a global provider of life sciences, diagnostics, and applied chemical measurement solutions. The company designs, manufactures, and sells instruments, software, services, and consumables that enable laboratory analysis and workflow productivity. Its core activities serve research, development, quality control, and regulatory compliance needs across multiple industries. Agilent's product lines include liquid chromatography, gas chromatography, mass spectrometry, spectroscopy, polymerase chain reaction, and microarray systems. These tools are employed to identify, quantify, and analyze the chemical and biological composition of samples. The company operates in more than 110 countries, serving customers through a network of direct sales representatives and distributors.

Agilent generates revenue primarily through the sale of its analytical instruments and associated consumables such as columns, cartridges, and reagents. The company also earns income from service contracts, repair and maintenance offerings, and software subscriptions. Additionally, Agilent derives revenue from licensing its technology and providing tailored solutions to address specific customer challenges. Its customers include laboratories in the pharmaceutical, biotechnology, chemical, food, environmental, and clinical sectors. Revenue is recognized upon delivery of products or completion of services in accordance with contractual terms.

The company operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab.

• Life Sciences and Applied Markets: This segment provides instruments, consumables, software, and services for applications such as chromatography, mass spectrometry, spectroscopy, and vacuum technology. It supports workflows in drug discovery, development, and manufacturing, as well as in food safety, environmental testing, and chemical analysis. The segment's offerings include liquid chromatography systems, gas chromatography systems, mass spectrometers, and related software platforms.

• Diagnostics and Genomics: This segment offers solutions for nucleic acid analysis, protein analysis, and cellular analysis, including PCR systems, microarrays, and related reagents. It serves clinical diagnostics, genomic research, and applied markets such as forensic and agricultural testing. Products include real time PCR instruments, digital PCR systems, and microarray scanners.

• Agilent CrossLab: This segment delivers instrument repair, preventive maintenance, compliance services, and consumable resale to support customer laboratory operations. CrossLab provides multi vendor service coverage, helping customers maintain instrument uptime and meet regulatory requirements. The segment also offers spare parts, consumables, and workflow optimization consulting.

Agilent holds a leading position in the analytical instrumentation market, competing with companies such as Thermo Fisher Scientific, Danaher Corporation, PerkinElmer, and Bruker Corporation. Its competitive advantages stem from a broad product portfolio, strong brand recognition, extensive global service network, and continuous investment in research and development. In fiscal year 2023, Agilent invested approximately $1.2 billion in research and development activities. The company allocates a significant portion of its revenue to R&D, enabling the introduction of new technologies and performance enhancements. Agilent's global footprint includes manufacturing, sales, and service facilities in North America, Europe, Asia Pacific, and other regions.

Agilent serves a diverse customer base that includes pharmaceutical and biotechnology firms, chemical and petrochemical companies, food and beverage producers, environmental testing laboratories, hospitals, clinical diagnostics labs, government agencies, and academic research institutions.

Investment Thesis

▲ Bull case

Agilent’s Ignite operating system is demonstrably delivering compounding structural benefits that the market underestimates, particularly in how it is accelerating innovation cycles and enabling strategic pricing power. The system facilitated a 200 basis point pricing contribution in Q2 alone, exceeding the full-year target of 100 basis points, and directly enabled the 9.5k ICPMS launch to be expedited by a full quarter through dynamic resource allocation and cross-functional execution. This operational discipline is not merely improving margins but is creating a sustainable advantage in new product introduction speed, allowing Agilent to capture share in high-growth areas like advanced materials and environmental testing faster than competitors. The market appears to be pricing in Ignite as a one-time efficiency play rather than recognizing its role as a continuous innovation catalyst that lowers the cost and increases the success rate of R&D investments, which is critical for long-term growth in instrument-centric businesses.
The Biocare acquisition presents a significant, underappreciated catalyst for Agilent’s diagnostics and life sciences growth trajectory, particularly in expanding its antibody menu and companion diagnostics capabilities. Management highlighted that Biocare’s clinically focused antibody menu will directly strengthen Agilent’s cancer diagnostics business, which already showed low double-digit growth in Q2 driven by the Omnis family and is poised to benefit from expanded PD-L1 testing indications on the Dako Omnis platform. The integration is being treated as a near-term priority under Ignite, with pre-close preparations ensuring readiness to hit the ground running post-close, yet the market has not fully priced in the potential for Biocare to drive mid-teens growth in the advanced therapeutics division (formerly specialty CDMO) and accelerate recurring revenue from consumables and services tied to Omnis platform adoption. This vertical integration in diagnostics creates a defensible, high-margin growth stream that is less cyclical than instrument sales and aligns with secular trends in personalized medicine and immunotherapy companion diagnostics.
Agilent’s strategic positioning in semiconductor-related advanced materials and chemical markets is benefiting from a multi-year CapEx upcycle that is broader and more durable than the market acknowledges, particularly in Asia ex-China and The Americas. While CAM growth was discussed in the context of semiconductor demand, the company explicitly noted strong performance in high-purity chemical companies supporting fabs and noted that the GC replacement cycle is underappreciated despite its 10-year instrument lifespan creating a very long, compounding tailwind. The market is likely viewing this as a temporary semiconductor-driven bounce, but Agilent’s leadership in GC and GCMS, combined with its differentiation in spectroscopy through innovations like the 9.5k ICPMS, suggests it is capturing share in a structural shift toward onshoring and supply chain resilience in critical materials sectors. This is further supported by the company’s observation of continued CapEx spending in semiconductors and batteries, which are not subject to the same volatility as memory chips and represent a more sustainable demand foundation for its analytical instrumentation.

Agilent’s Ignite operating system is demonstrably delivering compounding structural benefits that the market underestimates, particularly in how it is accelerating innovation cycles and enabling strategic pricing power. The system facilitated a 200 basis point pricing contribution in Q2 alone, exceeding the full-year target of 100 basis points, and directly enabled the 9.5k ICPMS launch to be expedited by a full quarter through dynamic resource allocation and cross-functional execution. This operational discipline is not merely improving margins but is creating a sustainable advantage in new product introduction speed, allowing Agilent to capture share in high-growth areas like advanced materials and environmental testing faster than competitors. The market appears to be pricing in Ignite as a one-time efficiency play rather than recognizing its role as a continuous innovation catalyst that lowers the cost and increases the success rate of R&D investments, which is critical for long-term growth in instrument-centric businesses.
The Biocare acquisition presents a significant, underappreciated catalyst for Agilent’s diagnostics and life sciences growth trajectory, particularly in expanding its antibody menu and companion diagnostics capabilities. Management highlighted that Biocare’s clinically focused antibody menu will directly strengthen Agilent’s cancer diagnostics business, which already showed low double-digit growth in Q2 driven by the Omnis family and is poised to benefit from expanded PD-L1 testing indications on the Dako Omnis platform. The integration is being treated as a near-term priority under Ignite, with pre-close preparations ensuring readiness to hit the ground running post-close, yet the market has not fully priced in the potential for Biocare to drive mid-teens growth in the advanced therapeutics division (formerly specialty CDMO) and accelerate recurring revenue from consumables and services tied to Omnis platform adoption. This vertical integration in diagnostics creates a defensible, high-margin growth stream that is less cyclical than instrument sales and aligns with secular trends in personalized medicine and immunotherapy companion diagnostics.
Agilent’s strategic positioning in semiconductor-related advanced materials and chemical markets is benefiting from a multi-year CapEx upcycle that is broader and more durable than the market acknowledges, particularly in Asia ex-China and The Americas. While CAM growth was discussed in the context of semiconductor demand, the company explicitly noted strong performance in high-purity chemical companies supporting fabs and noted that the GC replacement cycle is underappreciated despite its 10-year instrument lifespan creating a very long, compounding tailwind. The market is likely viewing this as a temporary semiconductor-driven bounce, but Agilent’s leadership in GC and GCMS, combined with its differentiation in spectroscopy through innovations like the 9.5k ICPMS, suggests it is capturing share in a structural shift toward onshoring and supply chain resilience in critical materials sectors. This is further supported by the company’s observation of continued CapEx spending in semiconductors and batteries, which are not subject to the same volatility as memory chips and represent a more sustainable demand foundation for its analytical instrumentation.

▼ Bear case

Agilent’s reliance on the instrument replacement cycle as a primary growth driver masks underlying vulnerability to capital expenditure volatility, particularly as macroeconomic headwinds from the Middle East conflict and inflationary pressures begin to impact customer spending patterns. While management highlighted strong LCMS and GC growth driven by replacement momentum, they acknowledged that Academia and Government (A&G) declined 5% in Q2 due to delayed government funding and multi-year grant uncertainty, a trend that could spread to other end markets if CapEx budgets tighten further. The company’s guidance assumes a recovery in government spending, but there is no clear visibility on when delayed funding in China and India for food testing or academic research will resume, creating a material risk to the food and A&G segments that are already underperforming. This dependency on cyclical CapEx makes Agilent’s growth less durable than implied by its Ignite-driven operational improvements, especially if global industrial investment slows amid persistent geopolitical and inflationary uncertainty.
The company’s expansion into AI-driven initiatives, while strategically sound, carries significant execution risk that the market is overlooking, particularly in how it plans to monetize AI across its product and operations portfolio. Management cited AI as a key FY26 enterprise focus area with potential to improve drug development ROI and upstream manufacturing QAQC workflows, yet provided no concrete details on revenue timelines, customer adoption rates, or specific AI-enabled product launches beyond vague references to future sharing of details. The collaboration with OpenAI and BCG is framed as a long-term capability build, but without near-term monetization pathways or clear metrics for success, there is a risk that AI investments become a drag on margins rather than a growth driver, especially given the history of AI initiatives in industrial tech failing to translate into meaningful revenue uplift. This uncertainty is compounded by the fact that Agilent’s AI efforts are not yet reflected in financial guidance, leaving investors to bet on unproven commercialization of a complex, cross-functional transformation.
Agilent’s China exposure presents a growing concern that is being underestimated due to the company’s emphasis on long-term alignment with national initiatives, despite near-term weakness that could persist longer than anticipated. Although management noted that China was roughly flat in the first half and expressed confidence in the stimulus driving recovery in FY27, the 9% Q2 decline was driven by softer-than-expected results in food and A&G due to funding delays, and the company acknowledged being over-indexed to applied markets in China while under-indexed to pharma. This imbalance is significant because applied markets (including environmental and industrial testing) are more sensitive to local government spending and industrial CapEx, which are showing signs of prolonged weakness beyond typical seasonal patterns. The stimulus is expected to benefit revenue only in the first part of next year, meaning the current weakness could extend through much of FY26, creating a persistent drag on overall growth that is not fully captured in the guidance range of 4.5% to 6.0% core growth, especially if the recovery in government spending is slower or less impactful than modeled.

Agilent’s reliance on the instrument replacement cycle as a primary growth driver masks underlying vulnerability to capital expenditure volatility, particularly as macroeconomic headwinds from the Middle East conflict and inflationary pressures begin to impact customer spending patterns. While management highlighted strong LCMS and GC growth driven by replacement momentum, they acknowledged that Academia and Government (A&G) declined 5% in Q2 due to delayed government funding and multi-year grant uncertainty, a trend that could spread to other end markets if CapEx budgets tighten further. The company’s guidance assumes a recovery in government spending, but there is no clear visibility on when delayed funding in China and India for food testing or academic research will resume, creating a material risk to the food and A&G segments that are already underperforming. This dependency on cyclical CapEx makes Agilent’s growth less durable than implied by its Ignite-driven operational improvements, especially if global industrial investment slows amid persistent geopolitical and inflationary uncertainty.
The company’s expansion into AI-driven initiatives, while strategically sound, carries significant execution risk that the market is overlooking, particularly in how it plans to monetize AI across its product and operations portfolio. Management cited AI as a key FY26 enterprise focus area with potential to improve drug development ROI and upstream manufacturing QAQC workflows, yet provided no concrete details on revenue timelines, customer adoption rates, or specific AI-enabled product launches beyond vague references to future sharing of details. The collaboration with OpenAI and BCG is framed as a long-term capability build, but without near-term monetization pathways or clear metrics for success, there is a risk that AI investments become a drag on margins rather than a growth driver, especially given the history of AI initiatives in industrial tech failing to translate into meaningful revenue uplift. This uncertainty is compounded by the fact that Agilent’s AI efforts are not yet reflected in financial guidance, leaving investors to bet on unproven commercialization of a complex, cross-functional transformation.
Agilent’s China exposure presents a growing concern that is being underestimated due to the company’s emphasis on long-term alignment with national initiatives, despite near-term weakness that could persist longer than anticipated. Although management noted that China was roughly flat in the first half and expressed confidence in the stimulus driving recovery in FY27, the 9% Q2 decline was driven by softer-than-expected results in food and A&G due to funding delays, and the company acknowledged being over-indexed to applied markets in China while under-indexed to pharma. This imbalance is significant because applied markets (including environmental and industrial testing) are more sensitive to local government spending and industrial CapEx, which are showing signs of prolonged weakness beyond typical seasonal patterns. The stimulus is expected to benefit revenue only in the first part of next year, meaning the current weakness could extend through much of FY26, creating a persistent drag on overall growth that is not fully captured in the guidance range of 4.5% to 6.0% core growth, especially if the recovery in government spending is slower or less impactful than modeled.

Business Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Diagnostics & Research

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	WAT	Waters Corp /De/	31,055.11 Bn	69,126.88	8,236.16	4.86 Bn
2	TMO	Thermo Fisher Scientific Inc.	191.02 Bn	27.63	4.23	43.16 Bn
3	DHR	Danaher Corp /De/	137.16 Bn	37.32	5.54	18.48 Bn
4	IDXX	Idexx Laboratories Inc /De	42.82 Bn	39.09	9.63	0.83 Bn
5	NTRA	Natera, Inc.	39.09 Bn	-172.71	15.63	0.02 Bn
6	A	Agilent Technologies, Inc.	37.61 Bn	26.60	5.20	0.30 Bn
7	IQV	Iqvia Holdings Inc.	34.23 Bn	35.84	2.06	15.83 Bn
8	ILMN	Illumina, Inc.	28.14 Bn	32.98	6.40	1.49 Bn

Research Tools

Developers

About

Investment Thesis

End Markets Breakdown of Revenue (2025)

Business Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

End Markets Breakdown of Revenue (2025)

Business Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password